Holen Sie sich die Stockscreener-App
0.1524
21.52%
-0.0576
Handel nachbörslich:
.15
-0.0024
-1.57%
Bio Path Holdings Inc Aktie (BPTH) Neueste Nachrichten
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Update - Defense World
Tevogen Bio Holdings Inc. stock trend outlook and recovery pathFree Long Hold Safe Return Strategy - Newser
Adicet Bio Inc. stock trend outlook and recovery pathLow Risk Picks for Daily Trading Released - metal.it
Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies and Breakthrough Therapies Shaping the Future Landscape - The Globe and Mail
TOPAZ REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS DEMONSTRATING STRONG ROYALTY AND INFRASTRUCTURE GROWTH - The Globe and Mail
Cutaneous T-Cell Lymphoma Pipeline Outlook Report 2025: Key 25+ Companies And Breakthrough Therapies Shaping The Future Landscape - Menafn.com
Antisense & RNAi Therapeutics Market Outlook 2025-2033: - GlobeNewswire
The Zacks Analyst Blog Highlights Meta Platforms, Alphabet, Microsoft and Tesla - The Globe and Mail
Antisense & RNAi Therapeutics Market Outlook 2025-2033: Advancements in Drug Delivery Propel Growth with Revenues Forecast to Reach $3.3 Billion by 2033 - Yahoo Finance
Tucows Announces Timing for Q2 2025 Financial Results News Release and Management Commentary - The Globe and Mail
Meta Platforms Is Helping Power This 6%-Yielding Dividend Stock's Continued Growth - The Globe and Mail
Google's AI push pays off with solid second quarter, but doubts about company's future persist - The Globe and Mail
Tevogen Bio Holdings Inc. Stock Analysis and ForecastFree Daily Trading Room Entry - Autocar Professional
What analysts say about Tevogen Bio Holdings Inc. stockFree Predictions - jammulinksnews.com
Cutaneous T-cell Lymphoma Market Anticipates Impressive - GlobeNewswire
Cutaneous T-cell Lymphoma Market Anticipates Impressive Growth Trajectory at a CAGR of 7.1% During the Study Period (2020–2034) | DelveInsight - GlobeNewswire
Cutaneous T-cell lymphoma Clinical Trials 2025: EMA, PDMA, FDA - openPR.com
Cutaneous T-cell lymphoma Clinical Trials 2025: EMA, PDMA, FDA Approvals, Medication, Therapies, Treatment Market, Mechanism of Action, Route of Administration, and Companies by DelveInsight - Barchart.com
Freeport-McMoRan to Post Q2 Earnings: What's in Store for the Stock? - The Globe and Mail
What drives Tevogen Bio Holdings Inc. stock priceFree Stock Selection - printweek.in
Carvana Is Up 100x Since the 2022 Lows. Could This Stock Be Next? - The Globe and Mail
Mullen Announces Plan to Change Company’s Name to Bollinger Innovations, Inc. and NASDAQ Approval for New Symbol — BINI - The Globe and Mail
Antisense Oligonucleotide Therapeutics Pipeline Appears - openPR.com
Antisense Oligonucleotide Therapeutics Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Menin Inhibitors Market Forecasts Signal Strong Uptake of Menin Inhibitors in Hematologic Oncology Across the 7MM During the Forecast Period (2020-2034) | DelveInsight - PR Newswire UK
Antisense Oligonucleotide Therapeutics Pipeline Appears Robust With 15+ Key Pharma Companies Actively Working In The Therapeutics Segment Delveinsight - Menafn.com
Oligonucleotides Competitive Landscape 2025: 320+ Therapies - openPR.com
Waldenstrom Macroglobulinemia Market Sees Surging Demand - GlobeNewswire
Waldenstrom Macroglobulinemia Market Sees Surging Demand Across the 7MM Amid BTK Inhibitor Advancements | DelveInsight - Business Upturn
Massive $888M Deal: Biotech Firm Makes Historic Pivot to Become Largest US Public HYPE Token Holder - Stock Titan
Where Will Arista Networks Be in 5 Years? - The Globe and Mail
30 Billion Reasons to Buy Oracle Stock Like There's No Tomorrow - The Globe and Mail
Top 5 AI Growth Stocks to Buy in July 2025 - The Globe and Mail
Delisting of Securities from The Nasdaq Stock Market - The Manila Times
Bio-Path Holdings announces executive resignations and operational pause - Investing.com
Bio-Path Holdings Faces Leadership Changes and Operational Pause, Considers Strategies Amid Limited Capital - AInvest
Bio-Path Holdings Faces Leadership Changes and Operational Pause - TipRanks
Cutaneous T Cell Lymphoma Pipeline Appears Robust With 25+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - Barchart.com
Oligonucleotides Clinical Trial Pipeline Analysis Demonstrates 280+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - SINA HONG KONG LIMITED
Life Sciences Investor Forum: Now Available for Online Viewing - The Manila Times
GitLab (NASDAQ:GTLB) Given New $60.00 Price Target at Wells Fargo & Company - Defense World
GRI Bio’s (GRI) Buy Rating Reaffirmed at HC Wainwright - Defense World
Short Interest in Bitcoin Depot Inc. (NASDAQ:BTMWW) Expands By 5,350.0% - Defense World
GitLab (NASDAQ:GTLB) Price Target Cut to $52.00 by Analysts at JPMorgan Chase & Co. - Defense World
Bio-Path Holdings, Inc. (NASDAQ:BPTH) Short Interest Up 870.6% in May - Defense World
Two Sigma Investments LP Cuts Position in Invesco Biotechnology & Genome ETF (NYSEARCA:PBE) - Defense World
Two Sigma Investments LP Reduces Stock Holdings in Industrial Logistics Properties Trust (NASDAQ:ILPT) - Defense World
Two Sigma Investments LP Makes New $273,000 Investment in ORIX Co. (NYSE:IX) - Defense World
Is Howmet Aerospace Stock Outperforming the S&P 500? - The Globe and Mail
Life Sciences Investor Forum Agenda Announced for June 11th-12th - GlobeNewswire
Bio-Path Holdings to Present at Life Sciences Virtual Investor F - GuruFocus
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum | BPTH Stock News - GuruFocus
Bio-Path Holdings to Present at Life Sciences Virtual Investor Forum - The Manila Times
Axsome Therapeutics Provides Update on the New Drug Application (NDA) for AXS-14 for the Management of Fibromyalgia - The Manila Times
Metsera Announces Positive Phase 1 Data of First-in-Class Once-Monthly Amylin Candidate MET-233i - The Manila Times
0.93%
0.15%
Kapitalisierung:
|
Volumen (24h):